Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 358
Filter
1.
Int. j. morphol ; 38(3): 611-615, June 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1098295

ABSTRACT

El incremento en las cifras de obesidad se debe esencialmente a factores de carácter ambiental asociados al consumo de alimentos con alto contenido de grasas saturadas. El objetivo del trabajo fue evaluar el efecto de una dieta alta en grasas sobre parámetros alimentarios y tejido adiposo blanco visceral. Se utilizaron ratas macho Sprague Dawley (n=10), divididas en dos grupos experimentales, el grupo control recibió dieta convencional (DC) y el grupo experimental una dieta alta en grasas (HFD), durante 10 semanas. Se determinó peso corporal, ingesta alimentaria, conversión alimenticia y características de tejido adiposo. El análisis de datos se realizó utilizando software IBM SPSS versión 21; tras evaluación de la normalidad de los datos, se aplicaron pruebas paramétricas T para muestras independientes y ANOVA de dos vías para medidas repetidas en uno de los factores, con ajuste Bonferroni. Se observó que el promedio de peso fue mayor en los animales alimentados con HFD, sin diferencia estadística respecto a DC, no obstante, existen diferencias significativas en el peso de las ratas alimentadas con HFD en distintos tiempos del protocolo, específicamente semanas 1, 5 y 10 (p<0,001). La ingesta alimentaria fue mayor en los animales alimentados con DC (p<0,005), sin embargo el consumo de energía fue mayor en aquellos alimentados con HFD (p=0,016), lo que derivó en una mayor conversión alimenticia (p<0,005). El promedio de diámetro teórico calculado de los adipocitos es estadísticamente mayor en grupo HFD (p<0,005), lo que se relaciona a la hipertrofia clásica generada tras un período de alimentación con elevado contenido de grasas. Conclusión: El protocolo permite establecer que efectivamente, dado la mayor densidad energética, HFD induce hipertrofia de los adipocitos, proceso característico de la obesidad.


The continued increase in obesity statistics is the result of environmental factors associated with the consumption of foods high in saturated fat. The objective of the work was to evaluate the effect of a high fat diet on food parameters and visceral white adipose tissue. in Male Sprague Dawley rats (n = 10) were used, divided into two experimental groups, the control group received conventional diet (DC) and the experimental group a high fat diet (HFD), for 10 weeks. Body weight, food intake, food conversion and adipose tissue characteristics were determined. Data analysis was performed using IBM SPSS version 21 software; after evaluating the normality of the data, parametric T tests were applied for independent samples and two-way ANOVA for repeated measurements in one of the factors, with Bonferroni adjustment. It was observed that the average weight was higher in animals fed with HFD, without statistical difference with respect to DC, however, there were significant differences in the weight of rats fed with HFD at different times of the protocol, specifically weeks 1.5 and 10 (p <0.001). Food intake was higher in animals fed DC (p <0.005), however the energy consumption was higher in those fed with HFD (p=0.016), which resulted in a higher feed conversion (p <0.005). The average theoretical diameter calculated for adipocytes is statistically higher in the HFD group (p <0.005), which is related to the classical hypertrophy generated after a period of feeding with high fat content. In conclusion, the protocol allows us to establish that, given the higher energy density, HFD induces adipocyte hypertrophy, a characteristic in the obesity process.


Subject(s)
Animals , Male , Rats , Adipose Tissue/drug effects , Diet, High-Fat/adverse effects , Obesity , Body Weight/drug effects , Analysis of Variance , Rats, Sprague-Dawley , Eating
2.
Int. j. morphol ; 38(3): 755-760, June 2020. tab, graf
Article in English | LILACS | ID: biblio-1098316

ABSTRACT

SUMMARY: The objective of this study was to describe the effects of monosodium glutamate on the collagen of the parotid gland in an obesity model. 18 newborn male Sprague Dawley rats were used (first control group; second group of MSG1: 4 mg/g of monosodium glutamate weight, 5 doses, and third group of MSG2: 4 mg/g of monosodium glutamate, 5 doses, maintained for 8 and 16 weeks respectively). The content and type of collagen were analyzed, in addition to the levels of cholesterol, glucose, triglycerides and uric acid. Monosodium glutamate produced an increase in the obesity rates of the MSG2 group, in addition to an increase in blood cholesterol, glucose and uric acid levels compared to the control group. Type III collagen in the MSG2 group showed a statistically significant increase. Monosodium glutamate induced obesity, in addition to an increase in type III collagen fibers.


RESUMEN: El objetivo de este estudio fue describir los efectos del glutamato monosódico sobre el colágeno de la glándula parótida en un modelo de obesidad. Se utilizaron 18 ratas Sprague Dawley machos recién nacidas (primer grupo control; segundo grupo MSG1: 4 mg/g de peso de glutamato monosódico, 5 dosis, y tercer grupo MSG2: 4 mg/g de glutamato monosódico, 5 dosis, mantenidas durante 8 y 16 semanas respectivamente). Se analizó el contenido y el tipo de colágeno, además de los niveles de colesterol, glucosa, triglicéridos y ácido úrico. El glutamato monosódico produjo un aumento en las tasas de obesidad del grupo MSG2, además de un aumento en los niveles de colesterol en sangre, glucosa y ácido úrico en comparación con el grupo control. El colágeno tipo III en el grupo MSG2 mostró un aumento estadísticamente significativo. La obesidad inducida por glutamato monosódico, además de un aumento en las fibras de colágeno tipo III.


Subject(s)
Animals , Male , Rats , Parotid Gland , Sodium Glutamate/toxicity , Collagen/drug effects , Obesity/chemically induced , Salivary Glands/drug effects , Triglycerides/blood , Uric Acid/blood , Blood Glucose/analysis , Body Weight/drug effects , Cholesterol/blood , Collagen/analysis , Rats, Sprague-Dawley , Disease Models, Animal , Animals, Newborn
3.
Int. j. morphol ; 38(1): 61-68, Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1056398

ABSTRACT

Fruit purees can be added to diet as alternative sources of bioactive compounds for the prevention and/or improvement of the complications of metabolic syndrome. In this work we evaluated the effect of the intake of low-fat diets enriched with fruit purees (guava-strawberry, guava-blackberry, guava-soursop, guava-passion fruit) on the body weight and biochemical markers in metabolic syndrome analogy (MSA)-induced rats. The rats (n=6 for each treatment) were induced with a high fat diet and were injected with streptozotocin, one dose every week for 4 consecutive weeks after fasting overnight, then healthy rats were fed with standard diet and MS rats were fed with standard diet plus each of the fruit puree, for 4 weeks. As novel findings, the diet enriched with fruit purees was associated with a reduction in body weight (~13-21 %) and a control in the metabolism of glucose by decreasing plasma glucose (~5963 %). Also, there was a reduction in the total cholesterol, triacylglycerols, low-density lipoproteins, and low enzymatic activities of alanine aminotransferase, alkaline phosphatase and γ-glutamyl transferase, useful metabolites in the control of inflammatory processes in the liver. A notable improvement in the liver morphology was observed indicating that the treatments had a hepatoprotective effect. The diet enriched with guava-blackberry puree caused the best results on most biochemical markers of MS rats. Therefore, diets enriched with fruit purees can be an alternative for MS individuals for the control and improvement of the complications caused by this syndrome.


Los purés de frutas se pueden agregar a la dieta como fuentes alternativas de compuestos bioactivos para la prevención y / o mejora de las complicaciones del síndrome metabólico. En este trabajo evaluamos el efecto de la ingesta de dietas bajas en grasas, enriquecidas con purés de frutas (guayaba-fresa, guayaba-mora, guayaba-guanábana, guayaba-maracuyá) sobre el peso corporal y los marcadores bioquímicos en el síndrome metabólico (SM) inducido en ratas. Las ratas (n = 6 para cada tratamiento) fueron inducidas con una dieta alta en grasas y se les inyectó estreptozotocina, una dosis cada semana durante 4 semanas consecutivas después de ayunar durante la noche. Luego, las ratas sanas fueron alimentadas con una dieta estándar; y las ratas con SM fueron alimentadas con dieta estándar más cada uno de los purés de frutas, durante 4 semanas. Como hallazgos novedosos, la dieta enriquecida con purés de frutas se asoció con una reducción en el peso corporal (~ 13-21 %) y un control en el metabolismo de la glucosa al disminuir la glucosa en plasma (~ 59-63 %). Además, hubo una reducción en el colesterol total, triacilgliceroles, lipoproteínas de baja densidad, y bajas actividades enzimáticas de alanina aminotransferasa, fosfatasa alcalina y gama-glutamil transferasa, metabolitos útiles en el control de los procesos inflamatorios en el hígado. Se observó una mejora notable en la morfología del hígado, lo que indica que los tratamientos tuvieron un efecto hepatoprotector. La dieta enriquecida con puré de guayaba y mora causó los mejores resultados en la mayoría de los marcadores bioquímicos de las ratas con SM. Por lo tanto, las dietas enriquecidas con purés de frutas pueden ser una alternativa para las personas con SM, para el control y la mejora de las complicaciones causadas por este síndrome.


Subject(s)
Animals , Rats , Diet, Fat-Restricted , Metabolic Syndrome , Fruit , Liver/drug effects , Blood Glucose/drug effects , Body Weight/drug effects , Biomarkers , Albumins/analysis , Disease Models, Animal , Alkaline Phosphatase/analysis , Hepatoprotector Drugs , Transaminases/analysis , Lipids/analysis , Liver/chemistry
4.
Einstein (Säo Paulo) ; 18: eAO4876, 2020. tab, graf
Article in English | LILACS | ID: biblio-1039734

ABSTRACT

ABSTRACT Objective To investigate the effects of sericin extracted from silkworm Bombyx mori cocoon on morphophysiological parameters in mice with obesity induced by high-fat diet. Methods Male C57Bl6 mice aged 9 weeks were allocated to one of two groups - Control and Obese, and fed a standard or high-fat diet for 10 weeks, respectively. Mice were then further subdivided into four groups with seven mice each, as follows: Control, Control-Sericin, Obese, and Obese-Sericin. The standard or high fat diet was given for 4 more weeks; sericin (1,000mg/kg body weight) was given orally to mice in the Control-Sericin and Obese-Sericin Groups during this period. Weight gain, food intake, fecal weight, fecal lipid content, gut motility and glucose tolerance were monitored. At the end of experimental period, plasma was collected for biochemical analysis. Samples of white adipose tissue, liver and jejunum were collected and processed for light microscopy analysis; liver fragments were used for lipid content determination. Results Obese mice experienced significantly greater weight gain and fat accumulation and had higher total cholesterol and glucose levels compared to controls. Retroperitoneal and periepididymal adipocyte hypertrophy, development of hepatic steatosis, increased cholesterol and triglyceride levels and morphometric changes in the jejunal wall were observed. Conclusion Physiological changes induced by obesity were not fully reverted by sericin; however, sericin treatment restored jejunal morphometry and increased lipid excretion in feces in obese mice, suggesting potential anti-obesity effects.


RESUMO Objetivo Investigar os efeitos da sericina extraída de casulos de Bombyx mori na morfofisiologia de camundongos com obesidade induzida por dieta hiperlipídica. Métodos Camundongos machos C57Bl6, com 9 semanas de idade, foram distribuídos em Grupos Controle e Obeso, que receberam ração padrão para roedores ou dieta hiperlipídica por 10 semanas, respectivamente. Posteriormente, os animais foram redistribuídos em quatro grupos, com sete animais cada: Controle, Controle-Sericina, Obeso e Obeso-Sericina. Os animais permaneceram recebendo ração padrão ou hiperlipídica por 4 semanas, período no qual a sericina foi administrada oralmente na dose de 1.000mg/kg de massa corporal aos Grupos Controle-Sericina e Obeso-Sericina. Parâmetros fisiológicos, como ganho de peso, consumo alimentar, peso das fezes em análise de lipídios fecais, motilidade intestinal e tolerância à glicose foram monitorados. Ao término do experimento, o plasma foi coletado para dosagens bioquímicas e fragmentos de tecido adiposo branco; fígado e jejuno foram processados para análises histológicas, e amostras hepáticas foram usadas para determinação lipídica. Resultados Camundongos obesos apresentaram ganho de peso e acúmulo de gordura significativamente maior que os controles, aumento do colesterol total e glicemia. Houve hipertrofia dos adipócitos retroperitoneais e periepididimais, instalação de esteatose e aumento do colesterol e triglicerídeos hepáticos, bem como alteração morfométrica da parede jejunal. Conclusão O tratamento com sericina não reverteu todas as alterações fisiológicas promovidas pela obesidade, mas restaurou a morfometria jejunal e aumentou a quantidade de lipídios eliminados nas fezes dos camundongos obesos, apresentando-se como potencial tratamento para a obesidade.


Subject(s)
Animals , Male , Anti-Obesity Agents/therapeutic use , Sericins/therapeutic use , Obesity/drug therapy , Time Factors , Triglycerides/analysis , Body Weight/drug effects , Gastrointestinal Transit/drug effects , Weight Gain/drug effects , Adipose Tissue/pathology , Cholesterol/analysis , Reproducibility of Results , Treatment Outcome , Anti-Obesity Agents/pharmacology , Sericins/pharmacology , Eating/drug effects , Fatty Liver/pathology , Diet, High-Fat/adverse effects , Glucose Tolerance Test , Liver/metabolism , Mice, Inbred C57BL , Mice, Obese , Obesity/etiology , Obesity/physiopathology
5.
Int. j. morphol ; 37(3): 1058-1066, Sept. 2019. graf
Article in Spanish | LILACS | ID: biblio-1012396

ABSTRACT

El consumo de fructosa ha aumentado en los últimos 50 años por la incorporación a la dieta de jarabe de maíz alto en fructosa (JMAF), presente en productos industrializados, como las bebidas azucaradas. Se puede asociar la ingesta de fructosa en altas concentraciones con el aumento de la obesidad y trastornos metabólicos. La fructosa, un azúcar natural que se encuentra en muchas frutas, se consume en cantidades significativas en las dietas occidentales. En cantidades iguales, es más dulce que la glucosa o la sacarosa y, por lo tanto, se usa comúnmente como edulcorante. Debido al incremento de obesidad entre la población joven y general y a los efectos negativos que puede tener a corto y largo plazo es importante considerar de donde provienen las calorías que se ingieren diariamente. Esta revisión describirá la relación entre el consumo de fructosa en altas concentraciones y el riesgo de desarrollar obesidad, resistencia a la insulina, lipogenesis de novo e inflamación.


The consumption of fructose has increased in the last 50 years due to the incorporation into the diet of high fructose corn syrup (HFCS), present in industrialized products, such as sugary drinks. The intake of fructose in high concentrations can be associated with the increase of obesity and metabolic disorders. Fructose, a natural sugar found in many fruits, is consumed in significant quantities in Western diets. In equal amounts, it is sweeter than glucose or sucrose and, therefore, is commonly used as a sweetener. Due to the increase of obesity among the young and general population and the negative effects that can have in the short and long term it is important to consider where the calories that are ingested daily come from. This review will describe the relationship between fructose consumption in high concentrations and the risk of developing obesity, insulin resistance, de novo lipogenesis, nonalcoholic fatty liver, inflammation and metabolic syndrome.


Subject(s)
Humans , Animals , Sweetening Agents/adverse effects , Insulin Resistance , Adipose Tissue/drug effects , Fructose/adverse effects , Obesity/chemically induced , Sweetening Agents/metabolism , Beverages , Body Weight/drug effects , Lipogenesis/drug effects , Fructose/metabolism , Glucose/adverse effects , Inflammation
6.
Int. j. morphol ; 37(2): 509-514, June 2019. tab, graf
Article in English | LILACS | ID: biblio-1002252

ABSTRACT

Cisplatin is an antineoplastic agent with neuropathy as one of its major side effect. However, effective treatment is lacking. Increasing evidence suggests that cisplatin might damage nerve capillaries leading to impaired functions of blood-nerve barrier (BNB) and neuropathy. This study was aimed to examine the effects of cisplatin on pericytes. Rats were either treated with intraperitoneal injection of cisplatin 2 mg/kg twice a week for five continuous weeks. Cisplatin-treated rats showed reduced body weight, thermal hypoalgesia and slow sciatic motor nerve conduction velocity, indicating neuropathy. The density of pericytes in the distal sciatic nerves determined by immunohistochemistry to desmin was significantly reduced in the cisplatin compared with that of the control groups. Electron microscopic analysis demonstrated the detachment of pericytes from endothelial cells including the disruption of shared basement membrane in the sciatic nerves from cisplatin-treated rats. These data indicate the pericyte loss and detachment caused by cisplatin. Future studies of the BNB components and functions after cisplatin treatment are needed and will be essential for the development of effective treatments against cisplatin-induced neuropathy.


El cisplatino es un agente antineoplásico y presenta como uno de sus principales efectos secundarios, la neuropatía. Sin embargo, falta un tratamiento eficaz. La creciente evidencia sugiere que el cisplatino podría dañar los capilares nerviosos, lo que puede provocar una alteración de las funciones de la barrera hematoencefálica (BHE) y neuropatía. Este estudio tuvo como objetivo examinar los efectos del cisplatino en los pericitos. Las ratas se trataron con inyección intraperitoneal de cisplatino (2 mg/kg) dos veces por semana durante 5 semanas seguidas. Las ratas tratadas con cisplatino mostraron una reducción del peso corporal, hipoalgesia térmica y una velocidad de conducción del nervio ciático lenta, lo que indicaría neuropatía. La densidad de los pericitos en los nervios ciáticos distales determinada por inmunohistoquímica para desmina se redujo significativamente en el grupo cisplatino en comparación con la de los grupos controles. El análisis al microscopio electrónico demostró el desprendimiento de pericitos de las células endoteliales, incluida la ruptura de la membrana basal compartida en los nervios ciáticos de ratas tratadas con cisplatino. Estos datos indican la pérdida de pericitos y el desprendimiento causado por el cisplatino. Se necesitan estudios futuros de los componentes y funciones del BHE después del tratamiento con cisplatino y serán esenciales para el desarrollo de tratamientos efectivos contra la neuropatía inducida por el cisplatino.


Subject(s)
Animals , Male , Rats , Cisplatin/toxicity , Pericytes/drug effects , Nervous System Diseases/pathology , Antineoplastic Agents/toxicity , Body Weight/drug effects , Immunohistochemistry , Rats, Wistar , Pericytes/pathology , Microscopy, Electron, Transmission , Nervous System Diseases/chemically induced
7.
Medicina (B.Aires) ; 79(2): 115-122, abr. 2019. tab
Article in English | LILACS | ID: biblio-1002617

ABSTRACT

Both total caloric intake and consumption of free sugars is higher than recommended. This situation contributes, among many other factors, to the increase of overweight and obesity in the population. To maintain the sweet taste of foods and beverages while reducing the caloric content and the amount of free sugars in said products, many people choose to replace sugary products in their diet for options containing non-caloric sweeteners. This change in their dietary choice is accompanied by an increasing number of consultations with health professionals about the effects that non-caloric sweeteners could have on their body weight. Results reported in different scientific publications seem contradictory in relation to this topic: some of them, showing a positive association between the consumption of non-caloric sweeteners and energy intake and body weight, while others reporting that the consumption of these additives -in replacement of sugar- may lead to a reduction in caloric intake and body weight. The main objective of this article is to review the available evidence on the consumption of non-caloric sweeteners in relation to body weight, thus providing another tool for health professionals to make nutritional recommendations based on the best available evidence.


Tanto la ingesta calórica total como el consumo de azúcares libres son mayores a los recomendados. Esta situación contribuye, entre muchos otros factores, al aumento del sobrepeso y la obesidad en la población. Para mantener el sabor dulce de los alimentos y bebidas, y a la vez reducir el contenido calórico y la cantidad de azúcares en los mismos, cada vez más personas optan por reemplazar los productos azucarados en su dieta por edulcorantes no calóricos. Este cambio dietario se acompaña de un creciente número de consultas con profesionales de la salud, sobre los efectos que los edulcorantes no calóricos podrían tener sobre el peso corporal. Resultados comunicados en diversas publicaciones científicas parecen contradictorios con relación a este tema, algunas informan una asociación positiva entre el consumo de edulcorantes no calóricos, la ingesta energética y el peso corporal, y otras muestran que el consumo de estos aditivos -en reemplazo del azúcar- lleva a una reducción de la ingesta calórica y a un descenso de peso. El principal objetivo de este artículo es repasar la evidencia disponible sobre el consumo de edulcorantes no calóricos con relación al peso corporal, brindando así una herramienta más para que los profesionales de la salud puedan hacer recomendaciones nutricionales basadas en la mejor evidencia disponible.


Subject(s)
Humans , Body Weight/drug effects , Non-Nutritive Sweeteners/pharmacology , Obesity/prevention & control , Energy Intake/drug effects , Weight Loss/drug effects , Body Mass Index , Dietary Sugars/adverse effects
8.
J. pediatr. (Rio J.) ; 95(1): 7-17, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-984644

ABSTRACT

Abstract Objectives: Human immunodeficiency virus infection can result in the early impairment of anthropometric indicators in children and adolescents. However, combined antiretroviral therapy has improved, in addition to the immune response and viral infection, the weight and height development in infected individuals. Therefore, the objective was to evaluate the effect of combined antiretroviral on the growth development of human immunodeficiency virus infected children and adolescents. Source of data: A systematic review was performed. In the study, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) strategy was used as the eligibility criterion. The MEDLINE-PubMed and LILACS databases were searched using these descriptors: HIV, children, growth, antiretroviral therapy. The objective was defined by the population, intervention, comparison/control, and outcome (PICO) technique. Inclusion and exclusion criteria were applied for study selection. Synthesis of data: Of the 549 studies indexed in MEDLINE-PubMed and LILACS, 73 were read in full, and 44 were included in the review (33 showed a positive impact of combined antiretroviral therapy on weight/height development, ten on weight gain, and one on height gain in children and adolescents infected with human immunodeficiency virus). However, the increase in growth was not enough to normalize the height of infected children when compared to children of the same age and gender without human immunodeficiency virus infection. Conclusions: Combined antiretroviral therapy, which is known to play a role in the improvement of viral and immunological markers, may influence in the weight and height development in children infected with human immunodeficiency virus. The earlier the infection diagnosis and, concomitantly, of malnutrition and the start of combined antiretroviral therapy, the lower the growth impairment when compared to healthy children.


Resumo Objetivos: A infecção pelo vírus da imunodeficiência humana pode comprometer, precocemente, os indicadores antropométricos de crianças e adolescentes. No entanto, a terapia antirretroviral combinada tem melhorado, além da resposta imunológica e da infecção viral, o ganho pôndero-estatural dos infectados. Dessa forma, nosso objetivo foi avaliar o efeito da terapia antirretroviral combinada no crescimento, de crianças e adolescentes, infectadas pelo vírus da imunodeficiência humana. Fonte dos dados: Foi realizada uma revisão sistemática. No estudo, adotou-se como critério de elegibilidade dos artigos, a estratégia PRISMA (preferred reporting items for systematic reviews and meta-analyses). Foram consultadas as bases de dados MEDLINE-PubMed e LILACS pelos descritores: HIV (vírus da imunodeficiência humana), children, growth, antiretroviral therapy. O objetivo foi definido pela estratégia PICO (population, intervention, comparison/control, outcome). Critérios de inclusão e exclusão foram aplicados na seleção dos estudos. Síntese dos dados: Dos 549 estudos indexados no MEDLINE-PubMed e LILACS, 73 foram lidos na íntegra - 44 incluídos na revisão (33 demonstraram impacto positivo da terapia antirretroviral combinada no ganho pôndero-estatural, dez no ganho de peso e um no de estatura, em crianças e adolescentes, infectados com vírus da imunodeficiência humana). No entanto, o incremento no crescimento não foi o suficiente para normalizar a estatura de crianças infectadas, quando comparado com crianças da mesma idade e sexo, sem infecção pelo vírus da imunodeficiência humana. Conclusões: A terapia antirretroviral combinada que, conhecidamente, atua na melhora de marcadores virais e imunológicos, pode influenciar no ganho pôndero-estatural de crianças infectadas com vírus da imunodeficiência humana. Quanto mais precoce o diagnóstico da infecção e, concomitante, desnutrição e início da terapia antirretroviral combinada, menores serão os prejuízos no crescimento, quando comparado às crianças saudáveis.


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Young Adult , Body Height/drug effects , Body Weight/drug effects , Child Development/drug effects , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Growth/drug effects , HIV Infections/drug therapy
9.
Acta cir. bras ; 34(7): e201900705, 2019. graf
Article in English | LILACS | ID: biblio-1038115

ABSTRACT

Abstract Purpose: The denervation of the intestine with benzalkonium chloride (BAC) reduces mortality and improves weight gain in rats with short bowel syndrome (SBS). Nevertheless, translating these promising findings from bench to bedside is not feasible because BAC promotes peritonitis and irreversible denervation which may be followed by an uncontrolled dilatation of the viscera. The use of botulinum toxin (BT) instead of BAC to achieve the denervation of the remaining small intestine in SBS could be an interesting option because it leads to a mild and transient denervation of the intestine. Methods: Here we evaluated the effects of the ileal denervation with BT in rats with SBS by verifying the body weight variation and intestinal morphological parameters. Four groups with 6 animals each were submitted to enterectomy with an ileal injection of saline (group E) or BT (group EBT). Control groups were submitted to simulated surgery with an ileal injection of BT (group BT) or saline (group C - control). Results: We observed that the treatment of the remaining ileum with BT completely reversed the weight loss associated to extensive small bowel resection. Conclusion: This may provide a new promising approach to the surgical treatment of SBS.


Subject(s)
Animals , Rats , Short Bowel Syndrome/surgery , Botulinum Toxins/pharmacology , Denervation/methods , Ileum/innervation , Short Bowel Syndrome/pathology , Benzalkonium Compounds/pharmacology , Body Weight/drug effects , Rats, Wistar , Muscle Weakness/pathology , Disease Models, Animal , Ileum/pathology , Jejunum/innervation
10.
Einstein (Säo Paulo) ; 17(3): eAO4635, 2019. tab, graf
Article in English | LILACS | ID: biblio-1012003

ABSTRACT

ABSTRACT Objective: To investigate the anti-hyperglycemic effects of Plathymenia reticulata hydroalcoholic extract and related changes in body weight, lipid profile and the pancreas. Methods: Diabetes was induced in 75 adult male Wistar rats via oral gavage of 65mg/Kg of streptozotocin. Rats were allocated to one of 8 groups, as follows: diabetic and control rats treated with water, diabetic and control rats treated with 100mg/kg or 200mg/kg of plant extract, and diabetic and control rats treated with glyburide. Treatment consisted of oral gavage for 30 days. Blood glucose levels and body weight were measured weekly. Animals were sacrificed and lipid profile and pancreatic tissue samples analyzed. Statistical analysis consisted of ANOVA, post-hoc Tukey-Kramer, paired Student's t and χ2 tests; the level of significance was set at 5%. Results: Extract gavage at 100mg/kg led to a decrease in blood glucose levels in diabetic rats in the second, third (198.71±65.27 versus 428.00±15.25) and fourth weeks (253.29±47.37 versus 443.22±42.72), body weight loss (13.22±5.70 versus 109.60±9.95) and lower cholesterol levels (58.75±3.13 versus 80.11±4.01) in control rats. Extract gavage at 200mg/Kg led to a decrease in glucose levels on the fourth week in diabetic rats, body weight loss in the second, third and fourth weeks in control rats, and lower cholesterol levels in diabetic and control rats. Islet hyperplasia (p=0.005) and pancreatic duct dilation (p=0.047) were observed in diabetic and control rats. Conclusion: Plathymenia extract reduced blood glucose levels in diabetic rats, and body weight in control rats, and promoted pancreatic islet hyperplasia in diabetic and control rats.


RESUMO Objetivo: Avaliar o efeito anti-hiperglicêmico do extrato hidroalcoólico de Plathymenia reticulata, alterações no peso, lipídeos e efeito sobre o pâncreas. Métodos: O diabetes foi induzido pela administração de estreptozotocina 65mg/kg, em 75 ratos Wistar adultos machos, divididos em 8 grupos diferentes: ratos diabéticos e controle + água, ratos diabéticos e controle + 100mg/kg ou 200mg/kg de extrato, ratos diabéticos e controle + gliburida. O tratamento foi realizado por gavagem (oral) por 30 dias. Níveis de glicose e peso foram verificados semanalmente. Os animais foram sacrificados, e amostras de lipídeos e do pâncreas foram analisadas. A análise estatística incluiu ANOVA, post-hoc Tukey-Kramer, teste t de Student pareado e teste do χ2, com nível de significância de 5%. Resultados: O extrato 100mg/kg promoveu redução nos níveis de glicose sanguínea em ratos diabéticos na segunda, terceira (198,71±65,27 versus 428,00±15,25) e quarta semanas (253,29±47,37 versus 443,22±42,72), perda de peso (13,22±5,70 versus 109,60±9,95) e diminuição do colesterol (58,75±3,13 versus 80,11±4,01) em ratos controle. Com extrato de 200mg/kg, houve redução dos níveis de glicose na quarta semana, nos ratos diabéticos; de peso na segunda, terceira e quarta semanas, nos ratos controle; e de colesterol nos animais diabéticos e controle. Ocorreram hiperplasia de ilhotas (p=0,005) e dilatação dos ductos pancreáticos (p=0,047) em ratos diabéticos e controles. Conclusão: O extrato de Plathymenia reduziu os níveis de glicose em ratos diabéticos e de peso em ratos controle, além de ter promovido hiperplasia de ilhotas pancreáticas em diabéticos e controles.


Subject(s)
Animals , Male , Rats , Plant Extracts/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/pharmacology , Fabaceae , Blood Glucose/analysis , Body Weight/drug effects , Cholesterol , Rats, Wistar , Streptozocin , Plant Leaves , Diabetes Mellitus, Experimental/chemically induced , Disease Models, Animal , Hyperplasia/pathology , Phytotherapy
11.
Arch. endocrinol. metab. (Online) ; 62(4): 424-430, July-Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-950077

ABSTRACT

ABSTRACT Objective: This analysis compared the efficacy and safety of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin, both added on to metformin. Materials and methods: This was a post-hoc analysis from a double-blind, randomized, 24-week clinical trial (NCT01606007) of patients with type 2 diabetes (T2D) inadequately controlled with metformin. We compared the dapagliflozin 10 mg (n = 179) and saxagliptin 5 mg (n = 176) treatment arms. Results: Dapagliflozin showed significantly greater mean reductions versus saxagliptin in HbA1c (difference versus saxagliptin [95% CI]: −0.32% [-0.54, −0.10]; p < 0.005), fasting plasma glucose (-0.98 [-1.42, −0.54] mmol/L; p < 0.0001), body weight (-2.39 [-3.08, −1.71] kg; p < 0.0001) and systolic blood pressure (SBP) (-3.89 [-6.15, −1.63] mmHg; p < 0.001). More dapagliflozintreated than saxagliptin-treated patients achieved the composite endpoint of HbA1c reduction ≥ 0.5%, weight loss ≥ 2 kg, SBP reduction ≥ 2 mmHg and no major/minor hypoglycemia (24% versus 7%). No major events of hypoglycemia were reported. More patients on dapagliflozin (6%) versus saxagliptin (0.6%) experienced genital infections. Conclusion: Dapagliflozin demonstrated greater glycemic efficacy than saxagliptin with additional benefits on weight and SBP, and the safety profile was consistent with previous studies.


Subject(s)
Humans , Male , Female , Middle Aged , Benzhydryl Compounds/therapeutic use , Adamantane/analogs & derivatives , Diabetes Mellitus, Type 2/drug therapy , Dipeptides/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Glucosides/therapeutic use , Benzhydryl Compounds/adverse effects , Blood Glucose/drug effects , Blood Pressure/drug effects , Body Weight/drug effects , Adamantane/adverse effects , Adamantane/therapeutic use , Double-Blind Method , Diabetes Mellitus, Type 2/blood , Dipeptides/adverse effects , Sodium-Glucose Transporter 2/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use
12.
Yonsei Medical Journal ; : 85-91, 2018.
Article in English | WPRIM | ID: wpr-742500

ABSTRACT

PURPOSE: Ascorbic acid has been reported to have an adipogenic effect on 3T3-L1 preadipocytes, while evidence also suggests that ascorbic acid reduces body weight in humans. In this study, we tested the effects of ascorbic acid on adipogenesis and the balance of lipid accumulation in ovariectomized rats, in addition to long-term culture of differentiated 3T3-L1 adipocytes. MATERIALS AND METHODS: Murine 3T3-L1 fibroblasts and ovariectomized rats were treated with ascorbic acid at various time points. In vitro adipogenesis was analyzed by Oil Red O staining, and in vivo body fat was measured by a body composition analyzer using nuclear magnetic resonance. RESULTS: When ascorbic acid was applied during an early time point in 3T3-L1 preadipocyte differentiation and after bilateral ovariectomy (OVX) in rats, adipogenesis and fat mass gain significantly increased, respectively. However, lipid accumulation in well-differentiated 3T3-L1 adipocytes showed a significant reduction when ascorbic acid was applied after differentiation (10 days after induction). Also, oral ascorbic acid administration 4 weeks after OVX in rats significantly reduced both body weight and subcutaneous fat layer. In comparison to the results of ascorbic acid, which is a well-known cofactor for an enzyme of collagen synthesis, and the antioxidant ramalin, a potent antioxidant but not a cofactor, showed only a lipolytic effect in well-differentiated 3T3-L1 adipocytes, not an adipogenic effect. CONCLUSION: Taking these results into account, we concluded that ascorbic acid has both an adipogenic effect as a cofactor of an enzymatic process and a lipolytic effect as an antioxidant.


Subject(s)
3T3-L1 Cells , Adipocytes/drug effects , Adipocytes/metabolism , Adipogenesis/drug effects , Animals , Antioxidants/pharmacology , Ascorbic Acid/pharmacology , Body Composition/drug effects , Body Weight/drug effects , Cell Differentiation/drug effects , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Lipolysis/drug effects , Mice , Ovariectomy , Rats, Sprague-Dawley
13.
Braz. j. med. biol. res ; 51(8): e7299, 2018. graf
Article in English | LILACS | ID: biblio-951744

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin resistance and attenuate hepatic steatosis but the specific underlying mechanism is unclear. This study was designed to investigate the underlying molecular mechanisms of exenatide therapy on NAFLD. We used in vivo and in vitro techniques to investigate the protective effects of exenatide on fatty liver via fat mass and obesity associated gene (FTO) in a high-fat (HF) diet-induced NAFLD animal model and related cell culture model. Exenatide significantly decreased body weight, serum glucose, insulin, insulin resistance, serum free fatty acid, triglyceride, total cholesterol, low-density lipoprotein, aspartate aminotransferase, and alanine aminotransferase levels in HF-induced obese rabbits. Histological analysis showed that exenatide significantly reversed HF-induced lipid accumulation and inflammatory changes accompanied by decreased FTO mRNA and protein expression, which were abrogated by PI3K inhibitor LY294002. This study indicated that pharmacological interventions with GLP-1 may represent a promising therapeutic strategy for NAFLD.


Subject(s)
Animals , Male , Rabbits , Peptides/pharmacology , Venoms/pharmacology , Protective Agents/pharmacology , Fatty Liver/metabolism , Non-alcoholic Fatty Liver Disease/drug therapy , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/drug effects , Blood Glucose/analysis , Body Weight/drug effects , In Vitro Techniques , Gene Expression Regulation/drug effects , Morpholines/metabolism , Chromones/metabolism , Disease Models, Animal , Eating/drug effects , Enzyme Inhibitors/metabolism , Fatty Liver/pathology , Diet, High-Fat , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics , Exenatide , Insulin/blood , Malondialdehyde/analysis , Obesity/metabolism
14.
Einstein (Säo Paulo) ; 16(2): eRC3961, 2018. graf
Article in English | LILACS | ID: biblio-891468

ABSTRACT

ABSTRACT The height response to the use of growth hormone in short height cases has already been confirmed in the literature. The influence of the insulin-like growth factor 1 (GH-IGF1) axis components on development, function, regeneration, neuroprotection, cognition, and motor functions has been evaluated in experimental studies and in adults with central nervous system lesions. However, there is still little research on the clinical impact of hormone replacement on neurological and psychomotor development. This report presents the case of a patient with excellent weight-height recovery and, even more surprisingly, neurological and psychomotor development in response to use of growth hormone. The result strengthens the correlation between experimental and clinical findings related to cerebral plasticity response to growth hormone in children. A preterm male patient with multiple health problems during the neonatal and young infancy period, who for six years presented with a relevant deficit in growth, bone maturation, and neurological and psychomotor development. At six years of age, he had low stature (z-score −6.89), low growth rate, and low weight (z-score −7.91). He was incapable of sustaining his axial weight, had not developed fine motor skills or sphincter control, and presented with dysfunctional swallowing and language. Supplementary tests showed low IGF-11 levels, with no changes on the image of the hypothalamus-pituitary region, and bone age consistent with three-year-old children — for a chronological age of six years and one month. Growth hormone replacement therapy had a strong impact on the weight-height recovery as well as on the neurological and psychomotor development of this child.


RESUMO A resposta estatural ao uso de hormônio do crescimento na baixa estatura já está comprovada na literatura. A influência dos componentes do eixo fator de crescimento semelhante à insulina tipo 1 (GH-IGF1) sobre desenvolvimento, função, regeneração, neuroproteção, cognição e funções motoras tem sido avaliada em estudos experimentais e em adultos com lesão de sistema nervoso central. No entanto, ainda são poucas as pesquisas sobre o impacto clínico da reposição hormonal no desenvolvimento neuropsicomotor. Este relato apresenta o caso de um paciente com excelente recuperação pôndero-estatural e, de forma ainda mais surpreendente, de desenvolvimento neuropsicomotor, em resposta ao uso de hormônio do crescimento. O resultado observado fortalece a correlação entre achados experimentais e clínicos, no que diz respeito à resposta da plasticidade cerebral ao hormônio do crescimento em crianças. Paciente do sexo masculino nasceu pré-termo com múltiplos agravos no período neonatal e de lactente jovem, e que, por 6 anos, apresentou deficit relevante do crescimento, na maturação óssea e do desenvolvimento neuropsicomotor. Aos 6 anos de idade, apresentava baixa estatura (escore Z de −6,89), baixa velocidade de crescimento e baixo peso (escore Z de −7,91). Era incapaz de sustentar o peso axial, não tinha desenvolvido habilidade motora fina e nem controle esfincteriano, e apresentava também disfunção na deglutição e na linguagem. Exames complementares mostraram IGF1 baixo, sem alterações na imagem da região hipotálamo-hipofisária e idade óssea compatível com 3 anos — para a idade cronológica de 6 anos e 1 mês. A terapia de reposição com hormônio do crescimento promoveu forte impacto na recuperação pôndero-estatural e também do desenvolvimento neuropsicomotor desta criança.


Subject(s)
Humans , Male , Child , Child Development/drug effects , Child Development/physiology , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Hormone Replacement Therapy/methods , Psychomotor Disorders/drug therapy , Time Factors , Body Height/drug effects , Body Height/physiology , Body Weight/drug effects , Body Weight/physiology , Treatment Outcome , Nervous System Diseases/drug therapy
15.
Rev. bras. psiquiatr ; 39(3): 228-236, July-Sept. 2017. graf
Article in English | LILACS | ID: biblio-899351

ABSTRACT

Objective: Sedation/somnolence are major side effects of pharmacotherapies for depression, and negatively affect long-term treatment compliance in depressed patients. Use of mirtazapine (MIR), an atypical antidepressant approved for the treatment of moderate to severe depression with comorbid anxiety disorders, is associated with significant sedation/somnolence, especially in short-term therapy. Nonetheless, studies with human subjects suggest that MIR-induced sedation is transient, especially when high and repeated doses are used. The purpose of this study was to explore the effects of acute and chronic administration of different doses of MIR on sedation in the rat. Methods: Assessment of sedation was carried out behaviorally using the rotarod, spontaneous locomotor activity, and fixed-bar tests. Results: A 15-mg/kg dose of MIR induced sedative effects for up to 60 minutes, whereas 30 mg/kg or more produced sedation within minutes and only in the first few days of administration. Conclusion: These results suggest that 30 mg/kg is a safe, well-tolerated dose of MIR which generates only temporary sedative effects.


Subject(s)
Animals , Male , Hypnotics and Sedatives/pharmacology , Locomotion/drug effects , Mianserin/analogs & derivatives , Antidepressive Agents, Tricyclic/pharmacology , Time Factors , Trazodone/administration & dosage , Trazodone/pharmacology , Body Weight/drug effects , Rats, Wistar , Rotarod Performance Test/methods , Dose-Response Relationship, Drug , Mirtazapine , Mianserin/administration & dosage , Mianserin/pharmacology , Antidepressive Agents, Tricyclic/administration & dosage
16.
Braz. j. med. biol. res ; 50(6): e6141, 2017. graf
Article in English | LILACS | ID: biblio-839302

ABSTRACT

Cannabinoid type 1 receptor (CB1R) inhibition tends to be one of the promising strategies for the treatment of obesity and other related metabolic disorders. Although CB1R inhibition may cause adverse psychiatric effects including depression and anxiety, the investigation of the role of peripheral CB1R on weight loss and related metabolic parameters are urgently needed. We first explored the effect of rimonabant, a selective CB1R antagonist/inverse agonist, on some metabolic parameters in high fat-diet (HFD)-induced obesity in mice. Then, real-time PCR and electrophysiology were used to explore the contribution of high voltage-activated Ca2+ channels (HVACCs), especially Cav1.1, on rimonabant's effect in skeletal muscle (SM) in HFD-induced obesity. Five-week HFD feeding caused body weight gain, and decreased glucose/insulin tolerance in mice compared to those in the regular diet group (P<0.05), which was restored by rimonabant treatment compared to the HFD group (P<0.05). Interestingly, HVACCs and Cav1.1 were decreased in soleus muscle cells in the HFD group compared to the control group. Daily treatment with rimonabant for 5 weeks was shown to counter such decrease (P<0.05). Collectively, our findings provided a novel understanding for peripheral CB1R's role in the modulation of body weight and glucose homeostasis and highlight peripheral CB1R as well as Cav1.1 in the SM as potential targets for obesity treatment.


Subject(s)
Animals , Male , Blood Glucose/drug effects , Calcium Channels/drug effects , Cannabinoid Receptor Antagonists/pharmacology , Muscle, Skeletal/drug effects , Piperidines/pharmacology , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Body Weight/drug effects , Calcium Channels, L-Type/drug effects , Calcium Channels, L-Type/metabolism , Calcium Channels/metabolism , Diet, High-Fat/adverse effects , Glucose Intolerance/etiology , Insulin Resistance , Mice, Inbred C57BL , Models, Animal , Muscle, Skeletal/metabolism , Obesity/etiology , Receptor, Cannabinoid, CB1/physiology
17.
Arch. endocrinol. metab. (Online) ; 60(6): 562-572, Nov.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-827785

ABSTRACT

ABSTRACT Objective To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3) therapy in patients with primary hypothyroidism. Subjects and methods This is a randomized, double-blind, crossover study. Adults with primary hypothyroidism (n = 32, age 42.6 ± 13.3, 30 females) on stable doses of LT4 for ≥ 6 months (125 or 150 μg/day) were randomized to continue LT4 treatment (G1) or to start LT4/LT3 therapy (75/15 μg/day; G2). After 8 weeks, participants switched treatments for 8 more weeks. Thyroid function, lipid profile, plasma glucose, body weight, electrocardiogram, vital signs, and quality of life (QoL) were evaluated at weeks 0, 8 and 16. Results Free T4 levels were significantly lower while on LT4/LT3 (G1: 1.07 ± 0.29 vs. 1.65 ± 0.46; G2: 0.97 ± 0.26 vs. 1.63 ± 0.43 ng/dL; P < 0.001). TSH and T3 levels were not affected by type of therapy. More patients on LT4/LT3 had T3 levels above the upper limit (15% vs. 3%). The combination therapy led to an increase in heart rate, with no significant changes in electrocardiogram or arterial blood pressure. Lipid profile, body weight and QoL remained unchanged. Conclusions The combination therapy yielded significantly lower free T4 levels, with no changes in TSH or T3 levels. More patients on LT4/T3 had elevated T3 levels, with no significant alterations in the evaluated outcomes. No clear clinical benefit of the studied formulation could be observed. Future trials need to evaluate different formulations and the impact of the combined therapy in select populations with genetic polymorphisms.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use , Hypothyroidism/drug therapy , Quality of Life , Thyroid Function Tests , Thyroxine/blood , Thyroxine/pharmacology , Triiodothyronine/blood , Triiodothyronine/pharmacology , Blood Glucose/analysis , Body Weight/drug effects , Thyrotropin/drug effects , Cholesterol/blood , Double-Blind Method , Cross-Over Studies , Drug Combinations , Hypothyroidism/blood
18.
Arq. bras. cardiol ; 107(2): 147-153, Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-794560

ABSTRACT

Abstract Background: Thyroid hormone deficiency during fetal life could affect the cardiac function in later life. The mechanism underlying this action in fetal hypothyroidism (FH) in rats has not been elucidated thus far. Objective: The aim of this study is to evaluation the effect of FH on cardiac function in male rats and to determine the contribution of α-myosin heavy chain (MHC) and β-MHC isoforms. Methods: Six pregnant female rats were randomly divided into two groups: The hypothyroid group received water containing 6-propyl-2-thiouracil during gestation and the controls consumed tap water. The offspring of the rats were tested in adulthood. Hearts from the FH and control rats were isolated and perfused with langendroff setup for measuring hemodynamic parameters; also, the heart mRNA expressions of α- MHC and β-MHC were measured by qPCR. Results: Baseline LVDP (74.0 ± 3.1 vs. 92.5 ± 3.2 mmHg, p < 0.05) and heart rate (217 ± 11 vs. 273 ± 6 beat/min, p < 0.05) were lower in the FH rats than controls. Also, these results showed the same significance in ±dp/dt. In the FH rats, β-MHC expression was higher (201%) and α- MHC expression was lower (47%) than control. Conclusion: Thyroid hormone deficiency during fetal life could attenuate normal cardiac functions in adult rats, an effect at least in part due to the increased expression of β-MHC to α- MHC ratio in the heart.


Resumo Fundamento: Deficiência de hormônio da tireoide durante vida fetal pode afetar a função cardíaca no futuro. O mecanismo subjacente dessa ação em hipotireoidismo fetal (HF) em ratos ainda não tem explicação. Objetivo: O objetivo desse estudo é avaliar o efeito de HF na função cardíaca em ratos macho e determinar a contribuição da α-miosina de cadeia pesada (α-MCP) e de isoformas β-MCP. Métodos: Seis ratos fêmea gestantes foram aleatoriamente divididas em dois grupos. O grupo do hipotireoidismo recebeu água contendo 6-propil-2-tiouracil durante a gestação, e os ratos no grupo de controle receberam água de torneira. Os filhotes dos ratos foram testados quando atingiram idade adulta. O coração dos ratos HF e controle foram isolados e submetidos a perfusão pelo método de Langendorff para medição de parâmetros hemodinâmicos. Também foram medidas as expressões de mRNA do coração de α-MCP e β-MCP por qPCR. Resultados: PVED de base (74,0 ± 3,1 vs. 92,5 ± 3,2 mmHg, p < 0,05) e pressão arterial (217 ± 11 vs. 273 ± 6 batidas/min, p < 0,05) mostraram-se mais baixas em ratos HF do que em ratos controle. Além disso, esses resultados mostraram a mesma significância em ±dp/dt. Em ratos HF, a expressão de β-MCP foi mais alta (201%) e a de α-MCP foi mais baixa (47%) do que em ratos controle. Conclusão: Deficiência de hormônio da tireoide durante a vida fetal pode enfraquecer funções cardíacas normais em ratos adultos, efeito devido em parte à expressão aumentada de β-MCP em relação a α-MCP no coração.


Subject(s)
Animals , Male , Female , Pregnancy , Body Weight/drug effects , Myosin Heavy Chains/metabolism , Congenital Hypothyroidism/metabolism , Myocardium/metabolism , Propylthiouracil , Antithyroid Agents , Thyroxine/blood , Triiodothyronine/blood , RNA, Messenger/metabolism , Random Allocation , Rats, Wistar , Ventricular Pressure , DNA, Complementary/metabolism , Congenital Hypothyroidism/chemically induced , Congenital Hypothyroidism/blood , Disease Models, Animal , Heart Rate
19.
Acta cir. bras ; 31(7): 434-441, tab, graf
Article in English | LILACS | ID: lil-787265

ABSTRACT

ABSTRACT PURPOSE: To investigate changes in the serum concentration and renal expression of IL-1 and TNF-α cytokines in rats that received sevoflurane and glibenclamide prior to hemorrhage. METHODS: Two groups of sevoflurane-anesthetized Wistar rats (n=10): G1 (control) and G2 (glibenclamide, 1 µg/g i.v.); hemorrhage of 30% blood volume (10% every 10 min), with replacement using Ringer solution, 5 ml/kg/h. Serum concentrations of IL-1 and TNF-α were studied in the first hemorrhage (T1) and 50 min later (T2), renal expression, at T2. RESULTS: In serum, G1 TNF-α (pg/mL) was T1=178.6±33.5, T2=509.2±118.8 (p<0.05); IL-1 (pg/mL) was T1=148.8±31.3, T2=322.6±115.4 (p<0.05); in G2, TNF-α was T1=486.2±83.6, T2=261.8±79.5 (p<0.05); IL-1 was T1=347.0±72.0, T2= 327.3±90.9 (p>0.05). The expression of TNF-α and IL-1 in the glomerular and tubular cells was significantly higher in the G2 group. CONCLUSIONS: Hemorrhage and glibenclamide elevated TNF-α and IL-1 concentrations in serum and kidneys. High levels of TNF-α already present before the hemorrhage in the glibenclamide group may have attenuated the damages found in the kidneys after the ischemia event.


Subject(s)
Animals , Shock, Hemorrhagic/metabolism , Interleukin-1/metabolism , Tumor Necrosis Factor-alpha/metabolism , Glyburide/pharmacology , Hypoglycemic Agents/pharmacology , Kidney/drug effects , Body Weight/drug effects , Random Allocation , Rats, Wistar , Anesthetics, Inhalation/administration & dosage , Models, Animal , KATP Channels/antagonists & inhibitors , Kidney/blood supply , Kidney/metabolism , Kidney Tubules/drug effects , Kidney Tubules/metabolism , Methyl Ethers/administration & dosage
20.
Int. j. morphol ; 34(2): 514-521, June 2016. ilus
Article in English | LILACS | ID: lil-787031

ABSTRACT

This study aimed to determine the antioxidant capacity of the Leucaena leucocephala aqueous shoot tips plus young leaves (LL-spl) extracts among three different fractions (LL-spl 10, 20, and 40 min) and to examine its acute toxicity on male reproductive parameters. The amount of the total phenolics in LL-spl extract was determined using a Folin-Ciocalteu reagent method and its antioxidant capacity was analyzed using 1, 1-diphenyl l-2-picrylhydrazyl radical scavenging and ferric reducing antioxidant powder methods. The LL-spl extract fraction with highest antioxidant capacity was used in animal treating. Male rats were divided into three groups (n= 5); control and groups treated with LL-spl 400 and 600 mg/Kg body weight for consecutive 40 days. The results showed that the LL-spl 40 min fraction possessed the highest antioxidant capacity. In addition, the LL-spl 400 and 600 groups showed no differences in weights of body, testis and epididymis, serum testosterone levels, and expression of testicular steroidogenic acute regulatory (StAR) protein. Significantly, LL-spl extract reduced the weight of seminal vesicle, sperm concentration, and seminiferous diameters compared with control. Moreover, LL-spl extract had adverse effect on testicular histology in inducing of seminiferous atrophy and degeneration including dilated blood vessels in interstitial tissue. It was concluded that although LL-spl extract possessing antioxidant capacity, in short term consumptions, it could be toxic to some male reproductive organs especially damaging testicular tissues.


El objetivo fue determinar la capacidad antioxidante del extracto de brotes acuosos con hojas nuevas de Leucaena leucocephala (LL-spl) en tres fracciones diferentes (LL-SPL 10, 20 y 40 min), además de examinar su toxicidad aguda sobre los parámetros reproductivos masculinos. Se determinó la cantidad de los fenoles totales en el extracto de LL-spl utilizando un método reactivo de Folin-Ciocalteu. La capacidad antioxidante se analizó por medio de 1-difenil-2-picrilhidracilo y/o métodos de reducción férrica de la capacidad antioxidante. La fracción de extracto LL-spl con mayor capacidad antioxidante fue utilizada en el tratamiento de los animales. Ratas macho fueron divididas en tres grupos (n= 5): el control y los grupos tratados con LL-spl 400 y 600 mg/kg peso corporal por 40 días consecutivos. El resultado mostró que la fracción LL-spl 40 min poseía la mayor capacidad antioxidante. Además, los grupos 400 y 600 LL-spl no mostraron diferencias según el peso corporal, testículos y epidídimo, niveles de testosterona y la expresión de proteínas testiculares. El extracto de LL-spl redujo de manera significativa el peso de la vesícula seminal, la concentración de espermatozoides y los diámetros de los túbulos seminíferos en comparación con el control. Por otra parte, el extracto de LL-spl tuvo un efecto adverso sobre la histología testicular por la inducción de atrofia y degeneración de los túbulos seminíferos, incluyendo a vasos sanguíneos dilatados en el tejido intersticial. Si bien el extracto LL-spl posee una capacidad antioxidante, ésta podría ser tóxica en el consumo a corto plazo para algunos órganos reproductores masculinos y especialmente dañino para los tejidos testiculares.


Subject(s)
Animals , Male , Rats , Antioxidants/pharmacology , Fabaceae , Plant Extracts/pharmacology , Plant Leaves/chemistry , Testis/drug effects , Body Weight/drug effects , Genitalia, Male/drug effects , Phenols/analysis , Rats, Sprague-Dawley , Seminiferous Tubules , Testosterone/analysis , Toxicity Tests, Acute
SELECTION OF CITATIONS
SEARCH DETAIL